Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/24132
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | CARVALHO, Katia C. | - |
dc.contributor.author | CUNHA, Isabela W. | - |
dc.contributor.author | ROCHA, Rafael M. | - |
dc.contributor.author | AYALA, Fernanda R. | - |
dc.contributor.author | CAJAIBA, Mariana M. | - |
dc.contributor.author | BEGNAMI, Maria D. | - |
dc.contributor.author | VILELA, Rafael S. | - |
dc.contributor.author | PAIVA, Geise R. | - |
dc.contributor.author | ANDRADE, Rodrigo G. | - |
dc.contributor.author | SOARES, Fernando A. | - |
dc.date.accessioned | 2017-11-27T17:05:53Z | - |
dc.date.available | 2017-11-27T17:05:53Z | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | CLINICS, v.66, n.6, p.965-972, 2011 | - |
dc.identifier.issn | 1807-5932 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/24132 | - |
dc.description.abstract | OBJECTIVE: To analyze glucose transporter 1 expression patterns in malignant tumors of various cell types and evaluate their diagnostic value by immunohistochemistry. INTRODUCTION: Glucose is the major source of energy for cells, and glucose transporter 1 is the most common glucose transporter in humans. Glucose transporter 1 is aberrantly expressed in several tumor types. Studies have implicated glucose transporter 1 expression as a prognostic and diagnostic marker in tumors, primarily in conjunction with positron emission tomography scan data. METHODS: Immunohistochemistry for glucose transporter 1 was performed in tissue microarray slides, comprising 1955 samples of malignant neoplasm from different cell types. RESULTS: Sarcomas, lymphomas, melanomas and hepatoblastomas did not express glucose transporter 1. Forty-seven per cent of prostate adenocarcinomas were positive, as were 29% of thyroid, 10% of gastric and 5% of breast adenocarcinomas. Thirty-six per cent of squamous cell carcinomas of the head and neck were positive, as were 42% of uterine cervix squamous cell carcinomas. Glioblastomas and retinoblastomas showed membranous glucose transporter 1 staining in 18.6% and 9.4% of all cases, respectively. Squamous cell carcinomas displayed membranous expression, whereas adenocarcinomas showed cytoplasmic glucose transporter 1 expression. CONCLUSION: Glucose transporter 1 showed variable expression in various tumor types. Its absence in sarcomas, melanomas, hepatoblastomas and lymphomas suggests that other glucose transporters mediate the glycolytic pathway in these tumors. The data suggest that glucose transporter 1 is a valuable immunohistochemical marker that can be used to identify patients for evaluation by positron emission tomography scan. The function of cytoplasmic glucose transporter 1 in adenocarcinomas must be further examined. | - |
dc.description.sponsorship | Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) | - |
dc.description.sponsorship | Fundacao de Amparo a Pesquisa no Estado de Sao Paulo (FAPESP) | - |
dc.language.iso | eng | - |
dc.publisher | HOSPITAL CLINICAS, UNIV SAO PAULO | - |
dc.relation.ispartof | Clinics | - |
dc.rights | openAccess | - |
dc.subject | Glucose transporter 1 | - |
dc.subject | Immunohistochemistry | - |
dc.subject | Protein expression | - |
dc.subject | PET-scan | - |
dc.subject | Malignant tumors | - |
dc.subject.other | glucose-transporter glut1 | - |
dc.subject.other | human breast-cancer | - |
dc.subject.other | prostate-cancer | - |
dc.subject.other | prognostic markers | - |
dc.subject.other | cell carcinoma | - |
dc.subject.other | glucose-transporter-1 | - |
dc.subject.other | hypoxia | - |
dc.subject.other | gene | - |
dc.subject.other | localization | - |
dc.subject.other | proteins | - |
dc.title | GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker | - |
dc.type | article | - |
dc.rights.holder | Copyright HOSPITAL CLINICAS, UNIV SAO PAULO | - |
dc.identifier.doi | 10.1590/S1807-59322011000600008 | - |
dc.identifier.pmid | 21808860 | - |
dc.subject.wos | Medicine, General & Internal | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | CUNHA, Isabela W.:Hosp AC Camargo Fund Antonio Prudente, Dept Anat Pathol, Sao Paulo, Brazil | - |
hcfmusp.author.external | ROCHA, Rafael M.:Hosp AC Camargo Fund Antonio Prudente, Res Ctr, Sao Paulo, Brazil | - |
hcfmusp.author.external | AYALA, Fernanda R.:Hosp AC Camargo Fund Antonio Prudente, Res Ctr, Sao Paulo, Brazil | - |
hcfmusp.author.external | CAJAIBA, Mariana M.:Hosp AC Camargo Fund Antonio Prudente, Res Ctr, Sao Paulo, Brazil | - |
hcfmusp.author.external | BEGNAMI, Maria D.:Hosp AC Camargo Fund Antonio Prudente, Res Ctr, Sao Paulo, Brazil | - |
hcfmusp.author.external | VILELA, Rafael S.:Hosp AC Camargo Fund Antonio Prudente, Res Ctr, Sao Paulo, Brazil | - |
hcfmusp.author.external | PAIVA, Geise R.:Hosp AC Camargo Fund Antonio Prudente, Res Ctr, Sao Paulo, Brazil | - |
hcfmusp.author.external | ANDRADE, Rodrigo G.:Hosp AC Camargo Fund Antonio Prudente, Res Ctr, Sao Paulo, Brazil | - |
hcfmusp.author.external | SOARES, Fernando A.:Hosp AC Camargo Fund Antonio Prudente, Res Ctr, Sao Paulo, Brazil | - |
hcfmusp.description.beginpage | 965 | - |
hcfmusp.description.endpage | 972 | - |
hcfmusp.description.issue | 6 | - |
hcfmusp.description.volume | 66 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000293410000008 | - |
hcfmusp.origem.id | 2-s2.0-79961152254 | - |
hcfmusp.publisher.city | SAO PAULO | - |
hcfmusp.publisher.country | BRAZIL | - |
hcfmusp.relation.reference | Younes M, 1995, ANTICANCER RES, V15, P2895 | - |
hcfmusp.relation.reference | Reisser C, 1999, INT J CANCER, V80, P194 | - |
hcfmusp.relation.reference | Airley RE, 2007, CHEMOTHERAPY, V53, P233, DOI 10.1159/000104457 | - |
hcfmusp.relation.reference | Ciampi R, 2008, MOL CELL ENDOCRINOL, V291, P57, DOI 10.1016/j.mce.2008.05.003 | - |
hcfmusp.relation.reference | Fenske W, 2009, ENDOCR-RELAT CANCER, V16, P919, DOI 10.1677/ERC-08-0211 | - |
hcfmusp.relation.reference | Kang SS, 2002, JPN J CANCER RES, V93, P1123 | - |
hcfmusp.relation.reference | BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784 | - |
hcfmusp.relation.reference | Kawamura T, 2001, CANCER, V92, P634, DOI 10.1002/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X | - |
hcfmusp.relation.reference | Chandler JD, 2003, CANCER, V97, P2035, DOI 10.1002/cncr.11293 | - |
hcfmusp.relation.reference | NISHIOKA T, 1992, CANCER RES, V52, P3972 | - |
hcfmusp.relation.reference | NAGASE Y, 1995, J UROLOGY, V153, P798, DOI 10.1016/S0022-5347(01)67725-5 | - |
hcfmusp.relation.reference | Bos R, 2002, J CLIN ONCOL, V20, P379, DOI 10.1200/JCO.20.2.379 | - |
hcfmusp.relation.reference | Yasuda M, 2005, ONCOL REP, V14, P1499 | - |
hcfmusp.relation.reference | Baer SC, 1997, J AM ACAD DERMATOL, V37, P575, DOI 10.1016/S0190-9622(97)70174-9 | - |
hcfmusp.relation.reference | Groves AM, 2011, EUR J NUCL MED MOL I, V38, P46, DOI 10.1007/s00259-010-1590-2 | - |
hcfmusp.relation.reference | Cantuaria G, 2001, CANCER, V92, P1144, DOI 10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T | - |
hcfmusp.relation.reference | Takanaga H, 2010, FASEB J, V24, P2849, DOI 10.1096/fj.09-146472 | - |
hcfmusp.relation.reference | Furuta E, 2010, BBA-REV CANCER, V1805, P141, DOI 10.1016/j.bbcan.2010.01.005 | - |
hcfmusp.relation.reference | Shanbhogue AKP, 2010, J COMPUT ASSIST TOMO, V34, P479, DOI 10.1097/RCT.0b013e3181db2670 | - |
hcfmusp.relation.reference | Avril N, 2001, J NUCL MED, V42, P9 | - |
hcfmusp.relation.reference | Dierckx RA, 2008, EUR J NUCL MED MOL I, V35, P1544, DOI 10.1007/s00259-008-0758-5 | - |
hcfmusp.relation.reference | Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166 | - |
hcfmusp.relation.reference | YAMAMOTO T, 1990, BIOCHEM BIOPH RES CO, V170, P223, DOI 10.1016/0006-291X(90)91263-R | - |
hcfmusp.relation.reference | Wachsberger PR, 2002, MELANOMA RES, V12, P35, DOI 10.1097/00008390-200202000-00006 | - |
hcfmusp.relation.reference | Brown RS, 2002, NUCL MED BIOL, V29, P443, DOI 10.1016/S0969-8051(02)00288-3 | - |
hcfmusp.relation.reference | Wang BY, 2000, CANCER, V88, P2774, DOI 10.1002/1097-0142(20000615)88:12<2774::AID-CNCR16>3.0.CO;2-I | - |
hcfmusp.relation.reference | Gatenby RA, 2007, BRIT J CANCER, V97, P646, DOI 10.1038/sj.bjc.6603922 | - |
hcfmusp.relation.reference | Amann T, 2009, EXPERT OPIN THER TAR, V13, P1411, DOI 10.1517/14728220903307509 | - |
hcfmusp.relation.reference | WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309 | - |
hcfmusp.relation.reference | Grabellus F, 2010, J NUCL MED, V51, P1191, DOI 10.2967/jnumed.110.075721 | - |
hcfmusp.relation.reference | Binder C, 1997, ANTICANCER RES, V17, P4299 | - |
hcfmusp.relation.reference | Rao UNM, 1999, MODERN PATHOL, V12, P1001 | - |
hcfmusp.relation.reference | Rudlowski C, 2003, AM J CLIN PATHOL, V120, P691, DOI 10.1309/4KYNQM5862JW2GD7 | - |
hcfmusp.relation.reference | Badi AN, 2009, INT J PEDIATR OTORHI, V73, P1187, DOI 10.1016/j.ijporl.2009.03.024 | - |
hcfmusp.relation.reference | Ogawa J, 1997, INT J CANCER, V74, P189, DOI 10.1002/(SICI)1097-0215(19970422)74:2<189::AID-IJC9>3.0.CO;2-V | - |
hcfmusp.relation.reference | BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870 | - |
hcfmusp.relation.reference | Ayala FRR, 2010, MOLECULES, V15, P2374, DOI 10.3390/molecules15042374 | - |
hcfmusp.relation.reference | Thorens B, 2010, AM J PHYSIOL-ENDOC M, V298, pE141, DOI 10.1152/ajpendo.00712.2009 | - |
hcfmusp.relation.reference | Suganuma N, 2007, BJU INT, V99, P1143, DOI 10.1111/j.1464-410X.2007.06765.x | - |
hcfmusp.relation.reference | Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2 | - |
hcfmusp.relation.reference | Nakajo M, 2012, EUR J RADIOL, V81, P146, DOI 10.1016/j.ejrad.2010.08.010 | - |
hcfmusp.relation.reference | BROWN RS, 1993, CANCER, V72, P2979, DOI 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X | - |
hcfmusp.relation.reference | Chiche J, 2010, J CELL MOL MED, V14, P771, DOI 10.1111/j.1582-4934.2009.00994.x | - |
hcfmusp.relation.reference | Haber RS, 1998, CANCER, V83, P34, DOI 10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E | - |
hcfmusp.relation.reference | North PE, 2000, HUM PATHOL, V31, P11, DOI 10.1016/S0046-8177(00)80192-6 | - |
hcfmusp.relation.reference | Minamimoto R, 2011, ANN NUCL MED, V25, P45, DOI 10.1007/s12149-010-0428-0 | - |
hcfmusp.relation.reference | Ravazoula P, 2003, EUR J GYNAECOL ONCOL, V24, P544 | - |
hcfmusp.relation.reference | Baer S, 2002, LARYNGOSCOPE, V112, P393, DOI 10.1097/00005537-200202000-00034 | - |
hcfmusp.relation.reference | Buim MEC, 2010, ORAL ONCOL, V46, P166, DOI 10.1016/j.oraloncology.2009.11.009 | - |
hcfmusp.relation.reference | De Jong IJ, 2010, Q J NUCL MED MOL IM, V54, P543 | - |
hcfmusp.relation.reference | Drut R, 2007, INT J SURG PATHOL, V15, P166, DOI 10.1177/1066896906299123 | - |
hcfmusp.relation.reference | FUKUMOTO H, 1988, DIABETES, V37, P657, DOI 10.2337/diabetes.37.5.657 | - |
hcfmusp.relation.reference | Hao Lang-Song, 2009, Sichuan Da Xue Xue Bao Yi Xue Ban, V40, P44 | - |
hcfmusp.relation.reference | Heber D, 1992, JPEN J PARENTER ENTE, V16, pS60, DOI 10.1177/014860719201600605 | - |
hcfmusp.relation.reference | HO CL, 2010, RADIOLOGY 1109, DOI 10.1148/RADIOL.10100672 | - |
hcfmusp.relation.reference | ISSELBAC.KJ, 1972, NEW ENGL J MED, V286, P929 | - |
hcfmusp.relation.reference | Jans J, 2010, UROLOGY, V75, P786, DOI 10.1016/j.urology.2009.08.024 | - |
hcfmusp.relation.reference | KALLINOWSKI E, 1989, CANCER RES, V49, P3759 | - |
hcfmusp.relation.reference | Khandani AH, 2009, ANN NUCL MED, V23, P595, DOI 10.1007/s12149-009-0264-2 | - |
hcfmusp.relation.reference | Kim YW, 2006, PATHOL RES PRACT, V202, P759, DOI 10.1016/j.prp.2006.07.006 | - |
hcfmusp.relation.reference | NORTH PE, 2001, ARCH DERMATOL, V137, P1 | - |
hcfmusp.relation.reference | OLIVER RJ, 2003, EUR J CANCER, V13, P503 | - |
hcfmusp.relation.reference | Smith TAD, 1999, BRIT J BIOMED SCI, V56, P285 | - |
hcfmusp.relation.reference | Stokkel MPM, 2002, J CANCER RES CLIN, V128, P393, DOI 10.1007/s00432-002-0350-5 | - |
hcfmusp.relation.reference | Storto G, 2010, BRIT J HAEMATOL, V151, P195, DOI 10.1111/j.1365-2141.2010.08335.x | - |
hcfmusp.relation.reference | Usuda Katsuo, 2010, Gen Thorac Cardiovasc Surg, V58, P405, DOI 10.1007/s11748-010-0603-1 | - |
hcfmusp.relation.reference | Vander Heiden Matthew G, 2009, Science, V324, P1029, DOI 10.1126/science.1160809 | - |
hcfmusp.relation.reference | Vazquez A, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-58 | - |
hcfmusp.relation.reference | Wei Bo, 2009, Zhonghua Wei Chang Wai Ke Za Zhi, V12, P277 | - |
dc.description.index | MEDLINE | - |
hcfmusp.citation.scopus | 175 | - |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - LIM/58 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_CARVALHO_GLUT1_expression_in_malignant_tumors_and_its_use_2011.PDF | publishedVersion (English) | 2.93 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.